The safety of immunotherapy is monitored through a combination of clinical trials and post-marketing surveillance. Clinical trials help identify the spectrum of side effects and establish protocols for managing them. Post-marketing surveillance offers real-world data on the incidence and management of irAEs, allowing for ongoing assessment and adjustment of treatment protocols.
